FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents a therapeutic agent for treating rheumatoid arthritis administered in a dose of 4 mg/kg for 4 weeks and more that provides an equivalent concentration of the interleukin-6 receptor antibody (IL-6R antibody), containing the interleukin-6 receptor antibody (IL-6R antibody).
EFFECT: invention provides the simultaneous intensification of the therapeutic action on rheumatoid arthritis and reduced hypersensitivity.
46 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROPHYLACTIC DRUG FOR VASCULITIS | 2004 |
|
RU2379054C2 |
| THERAPEUTIC AGENT FOR TREATING DISEASES RELATED TO JUVENILE CHRONIC ARTHRITIS | 2002 |
|
RU2541165C2 |
| THERAPEUTIC AGENT FOR DISEASES, RELATED TO CHILDREN'S CHRONIC ARTHRITIC DISEASES | 2002 |
|
RU2361613C2 |
| THERAPEUTIC AGENT IN SPINAL MARROW INJURY CONTAINING INTERLEUKINE-6 ANTAGONIST | 2004 |
|
RU2358761C2 |
| THERAPEUTIC AGENT FOR MESOTHELIOMA | 2004 |
|
RU2554942C2 |
| THERAPEUTIC AGENT FOR MESOTHELIOMA | 2004 |
|
RU2392967C2 |
| DRUGS AGAINST CHRONIC RHEUMATIC ARTHRITIS CONTAINING ANTAGONIST OF IL-6 AS EFFECTIVE COMPONENT | 1995 |
|
RU2147443C1 |
| CHRONIC REJECTION INHIBITOR | 2008 |
|
RU2450829C2 |
| PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF DISEASES CAUSED BY IL-6 FORMATION | 1995 |
|
RU2147442C1 |
| AGENT FOR CARDIOPATHY | 2006 |
|
RU2450830C2 |
